BCAX vs DAL · $1.51B cap vs P/E 12, rev $61.64B
Bicara Therapeutics Inc. Common Stock (BCAX) versus Delta Air Lines Inc (DAL) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
BCAX does not have a complete income-statement cache yet.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
BCAX currently screens at market cap $1.51B. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Not investment advice. Open the BCAX and DAL stock pages for the full models.
Not investment advice.